A5103090825- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- MicroRNA in disease regulation
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Peptidase Inhibition and Analysis
- Ferroptosis and cancer prognosis
- Cancer Cells and Metastasis
- Circular RNAs in diseases
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Lipoproteins and Cardiovascular Health
- Microbial Natural Products and Biosynthesis
- HER2/EGFR in Cancer Research
- RNA modifications and cancer
- Cancer therapeutics and mechanisms
- Cancer, Stress, Anesthesia, and Immune Response
Hebei University
2022-2025
Shenyang University
2024-2025
Nanfang Hospital
2019-2025
Southern Medical University
2012-2025
Dalian Medical University
2025
Second Affiliated Hospital of Dalian Medical University
2025
Changchun University of Science and Technology
2022-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2024
Tianjin First Center Hospital
2024
Tianjin Medical University
2024
Although tumor mutation burden (TMB) has been well known to predict the response immune checkpoint inhibitors (ICI), lack of randomized clinical trial data restricted its application. This study aimed explore significance and feasibility biomarker combination based on TMB copy-number alteration (CNA) for prognosis each prediction ICI therapy in metastatic pan-cancer milieu.Non-ICI-treated MSK cohort was used analysis. Three independent immunotherapy cohorts, including non-small cell lung...
Adjuvant diet therapy is an important means of comprehensive treatment cancer. It recognized by patients for its high safety, painlessness, and ease to operate. However, the development adjuvant dietary limited unclear targets anticancer mechanisms. In this work, caffeic acid was found as inhibitor TMEM16A with IC50 29.47 ± 3.19 μM fluorescence quenching whole-cell patch-clamp experiments. Caffeic regulated proliferation, migration, apoptosis lung cancer cells targeting TMEM16A, which...
Liver kinase B1 (LKB1) mutation is prevalent and a driver of resistance to immune checkpoint blockade (ICB) therapy for lung adenocarcinoma. Here leveraging single cell RNA sequencing data, we demonstrate that trafficking adhesion process activated T cells are defected in genetically engineered Kras-driven mouse model with Lkb1 conditional knockout. LKB1 mutant cancer result marked suppression intercellular molecule-1 (ICAM1). Ectopic expression Icam1 Lkb1-deficient tumor increases homing...
Dysbiosis of the gut microbiota is emerging as a pivotal factor in pathogenesis colorectal cancer (CRC). Ginsenoside Rh4 (Rh4) an active compound isolated from ginseng with beneficial effects modulating intestinal inflammation and dysbiosis, but how regulates to alleviate CRC remains underexplored. We investigated impact on mechanism its action inhibiting via modulation microbiota. used AOM/DSS model employed transcriptomics, genomics metabolomics techniques explore inhibitory CRC....
Lung cancer is a malignant tumor with the highest morbidity and mortality rates. Food therapy common adjuvant treatment for lung due to its safety painlessness. Developing new functional food exploring novel drug targets important therapy. This study confirmed that active ingredient nuciferine of lotus leaf was TMEM16A inhibitor by whole-cell patch clamp experiments site-directed mutagenesis experiments. CCK8 assay, colony formation wound healing Annexin-V assay were combined prove inhibited...
Background Genetic variations of some driver genes in non-small cell lung cancer (NSCLC) had shown potential impact on immune microenvironment and associated with response or resistance to programmed death protein 1 (PD-1) blockade immunotherapy. We therefore undertook an exploratory analysis develop a genomic mutation signature (GMS) predict the anti-PD-(L)1 therapy. Methods In this multicohort analysis, 316 patients non-squamous NSCLC treated from three independent cohorts were included...
Purpose: Secondary chronic lymphedema is a complication that seriously affects the quality of life cancers survivors which urgent to be studied. However, current animal models generally have some defects such as short duration affect research process. To acquire an model easier accomplish well higher success rate main goal our experiment. Methods: The hind limb rats with secondary was established by near infrared fluorescence-guided lymphatic system destruction combined high-fat diet...
Abstract: Pericytes, also known as mural cells, are cells embedded between endothelial and the basement membrane of capillaries, where they orchestrate morphological functional homeostasis blood vessels. Within tumor microenvironment, pericytes interact closely with various cellular components, including stromal immune cells. Through these dynamic interactions, activated subsequently transform into tumor-associated (TPCs). The origin TPCs varies depending on tissue type, contributing to...
Significantly, the benzofuran-modified polycyclic molecules by regulating donor ability, which achieved a switch between thermally activated delayed fluorescence (TADF) and hybrid local charge transfer (HLCT) emissions.
Anti-PD-1 monoclonal antibody is becoming a standard treatment for advanced melanoma with durable responses and prolonged survival, but the prognosis still unsatisfactory patients liver metastases. Here, we analysed 5 clinical studies (second-line or above, JS001-I-PK, CT4, KN151, BGB-A317-102, SHR-1210-102, from 2015 to 2018) of anti-PD-1 monotherapy explore prognostic variables A total 187 were included, among which 47 had metastasis 140 did not. The objective response rate (ORR) non-liver...
Abstract Background Immune checkpoint inhibitor (ICI) therapy combined with conventional therapies is being broadly applied in non-small cell lung cancer (NSCLC) patients. However, the risk of interstitial pneumonitis (IP) following a regimen incompletely characterized. Methods A total 46,127 NSCLC patients were extracted for disproportionality analyses IP from Food and Drug Administration’s Adverse Event Reporting System (FAERS) database. 1108 who received ICI treatment at Nanfang Hospital...
IL-8 has been implicated in the malignant progression of various types cancers; however, precise molecular mechanisms associated with breast cancer (BRCA) are unclear.We analyzed clinical signature and immune characteristics BRCA patients its correlation expression using The Cancer Genome Atlas (TCGA) datasets. role epithelial-mesenchymal transition (EMT) was verified through Western blotting, Cell Counting Kit-8 assay, wound healing assays, as well cell invasion experiments.Through a...
Lung cancer has the highest rate of incidence and mortality among all cancers. Most chemotherapeutic drugs used to treat lung cause serious side effects are susceptible drug resistance. Therefore, exploring novel therapeutic targets for is important. In this study, we evaluated potential TMEM16A as a target cancer. Homoharringtonine (HHT) was identified natural product inhibitor TMEM16A. Patch-clamp experiments showed that HHT inhibited activity in concentration-dependent manner....
A substantial need for effective and safe treatment options is still unmet patients with heavily pre-treated human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Herein, we assessed the efficacy safety of pyrotinib plus trastuzumab chemotherapy in treated HER2-positive MBC.
Cancer is one of the most serious malignant diseases, and chemotherapy cancer's main clinical treatment method. However, inevitably produces drug resistance, side effects accompany them. Adjuvant therapy an effective way to enhance chemotherapeutic sensitivity reduce effects. This study found allicin, garlic's active ingredient, inhibitor transmembrane protein 16A (TMEM16A), a novel target lung adenocarcinoma. Allicin concentration-dependently inhibited TMEM16A currents with IC50 24.35 ±...